1. Adegboyega G, Ozair A, Kanmounye US, Bandyopadhyay S, Vaqas B (2021) Letter: is the stupp protocol an expensive and unsustainable standard of care for glioblastoma in low- and middle-income country settings? A Call to Action! Neurosurgery 89:E249–E251. https://doi.org/10.1093/neuros/nyab273
2. Balogun JA, Adekanmbi AA (2020) Management of glioblastoma: a perspective from Nigeria. Chin Clin Oncol 2:206–206. https://doi.org/10.21037/cco.2020.02.06
3. Ben Nasr S, Haddaoui A, Bach Hamba S, Lagha A, Labidi S, Afrit M, Benna F, Jmal H, Boussen H (2015) Glioblastoma in Tunisia: a retrospective study about 41 cases. Tunis Med 93:598–601
4. Chan DTM, Kam MKM, Ma BBY, Ng SCP, Pang JCS, Lau CKY, Siu DYW, Ng BSL, Zhu XL, Chen GG, Ng HK, Poon WS (2011) Association of molecular marker O(6)methylguanine DNA methyltransferase and concomitant chemoradiotherapy with survival in Southern Chinese glioblastoma patients. Hong Kong Med J = Xianggang yi xue za zhi 17:184–188
5. Erpolat OP, Akmansu M, Goksel F, Bora H, Yaman E, Büyükberber S (2009) Outcome of newly diagnosed glioblastoma patients treated by radiotherapy plus concomitant and adjuvant temozolomide: a long-term analysis. Tumori 95:191–197